Product Description: Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids[1][2].
Applications: Cancer-programmed cell death
Formula: C83H114N18O23S2
Citations: Cell Prolif. 2023 Mar 27;e13460./Cell Mol Life Sci. 2022 Sep 19;79(10):523./Stem Cell Res Ther. 2023 Oct 26;14(1):305.
References: [1]Nile AH, et, al. A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells. Nat Chem Biol. 2018 Jun;14(6):582-590./[2]Larasati Y, et, al. Unlocking the Wnt pathway: Therapeutic potential of selective targeting FZD7 in cancer. Drug Discov Today. 2022 Mar;27(3):777-792.
CAS Number: 2247635-23-8
Molecular Weight: 1796.05
Compound Purity: 98.44
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Wnt